Cresco Labs Inc. (CRLBF) Stock Price & Analysis
Cresco Labs Inc. (CRLBF) closed at USD 0.6 on Friday, October 23, 2026, down 5.51% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.64; the Oct 23, 2026 session ranged USD 0.6–0.63 on volume of 88,949 shares. Market capitalization is $222.14M, with a 52-week range of USD 0.57–2.3 (OQX). Source: Nexqual, retrieved October 24, 2026 at 14:10 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRLBF.md
Key facts (CRLBF)
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 2 (range 2–2).
- Total return with dividends: 1Y -50.8% vs S&P 500 +13.4%; 5Y -92.3% vs S&P 500 +76.9%.
- Next earnings: 2026-11-06, EPS estimate USD -0.03, revenue estimate $174M.
Analysts (CRLBF)
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 2 (low 2, high 2).
Total return (dividends reinvested) (CRLBF)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -50.8% | -92.3% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -50.9% | -40.2% |
| Volatility (annualized) | 121.8% | 87.8% |
| Max drawdown | -69.9% (Dec 2025→Oct 2026) | -95.5% (Nov 2021→Jun 2025) |
CRLBF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.03 | $0.00 | — | $173.7M | 1 |
| Next quarter (ends Dec 2026) | $-0.03 | $0.00 | — | $173.9M | 1 |
| Current fiscal year (ends Dec 2026) | $-0.04 | $-0.09 | -56.2% | $672.2M | 1 |
| Next fiscal year (ends Dec 2027) | $-0.04 | $-0.06 | -35.0% | $697.5M | 1 |
Key Statistics (as of October 24, 2026 at 14:10 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▼ 5.51% (down) |
| Previous Close | USD 0.64 |
| Open | USD 0.62 |
| Day Range | USD 0.6 – 0.63 |
| 52-Week Range | USD 0.57 – 2.3 |
| Volume | 88,949 shares |
| Market Cap | $222.14M |
| Exchange | OQX |
Technical Analysis (CRLBF)
Nexqual's technical model rates CRLBF "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 14:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.16 (neutral) |
| vs SMA50 | Below (USD 0.72) |
| MACD | -0.03 (negative) |
Analyst Ratings (CRLBF)
Wall Street analysts rate CRLBF "Buy" based on 6 analysts, with a mean price target of USD 2 (range USD 2–2), per Nexqual as of October 24, 2026 at 14:10 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 2 |
| High Target | USD 2 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (CRLBF)
| Next Earnings Date | 2026-11-06 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $173.66M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.06 vs est -0.03 ▲ beat |
| 2026-03-31 | USD -0.04 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.03 vs est -0.03 ▲ beat |
| 2025-09-30 | USD 0.01 vs est -0.04 ▲ beat |
Source: Nexqual, October 24, 2026 at 14:10 UTC.
Financials & Fundamentals (CRLBF)
| Total Revenue | $651.13M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.90% |
| Gross Margin | +49.93% |
| Operating Margin | +7.71% |
| Profit Margin | -15.50% |
| ROE | -36.06% |
| Debt / Equity | 2.25 |
| Current Ratio | 1.78 |
| Total Cash | $32.87M |
| Total Debt | $592.02M |
Source: Nexqual, October 24, 2026 at 14:10 UTC.
Financial Health Score (CRLBF)
Nexqual rates Cresco Labs Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 14:10 UTC.
| Growth | Weak — Revenue -9% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 50%, operating 8% (last 12 months) |
| Balance Sheet | Weak — $33M cash vs $592M debt |
| Cash Flow | Solid — Operating cash flow $43M (TTM) |
| Efficiency | Critical — ROE -36%, ROA 3.0% |
Ownership (CRLBF)
| Insider Ownership | +2.25% |
|---|---|
| Institutional Ownership | +3.39% |
| Shares Outstanding | 354.13M |
| Float | 345.07M |
Source: Nexqual, October 24, 2026 at 14:10 UTC.
Leadership (CRLBF)
Cresco Labs Inc. is led by Charles Bachtell, Co-Founder, CEO & Director, per Nexqual as of October 24, 2026 at 14:10 UTC.
| Co-Founder, CEO & Director | Charles Bachtell |
|---|---|
| President | Gregory Butler |
| Co-Founder & Independent Director | Robert M. Sampson |
| Senior VP, Corporate Controller & Interim CFO | Mark Stortz |
| Chief Operating Officer | Ty Gent |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.47 | ▼ 2.43% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 14:10 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt